Weed (BUDZ) Other Accumulated Expenses (2019 - 2020)
Weed's (BUDZ) quarterly Other Accumulated Expenses came in at $18500.0 in Q4 2020, up 85.0% year-on-year from $10000.0 in Q1 2020, and up 85.0% quarter-over-quarter from $10000.0 in Q4 2019.
Weed (BUDZ) Other Accumulated Expenses (2019 - 2020) Analysis & Trends
Weed's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $18500.0 for Q4 2020.
- On a quarterly basis, Other Accumulated Expenses rose 85.0% year-over-year to $18500.0 in Q4 2020; TTM through Dec 2020 was $18500.0, a 85.0% increase from a year earlier, with the FY2020 full-year figure at $18500.0, up 85.0% from the prior year.
- Other Accumulated Expenses rose to $18500.0 in Q4 2020 per BUDZ's latest filing, from $10000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $18500.0 in Q4 2020 and bottomed at $10000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn |
| 3 | Zoetis | 32.67 Bn | 30.73 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.69 Bn | 23.63 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.12 Bn | 20.97 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.24 Bn | 18.44 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.83 Bn | 16.51 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.22 Bn | 785.00 Mn |
| 10 | Weed | 2.77 Mn | 2.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 18,500.00 |
| Dec 31, 2019 | 10,000.00 |